TABLE 2.
Patient Characteristics
| Characteristics | N (%) | Therapy Completion | Discontinued Therapy | % Completed | Univariate Analysis* |
|---|---|---|---|---|---|
| All patients | 173 | 141 | 32 | 81.5 | |
| Sex | |||||
| Male | 100 (57.8) | 82 | 18 | 82.0 | 0.846 |
| Female | 73 (42.2) | 59 | 14 | 80.8 | |
| Age | |||||
| ≤40 | 6 (3.5) | 5 | 1 | 83.3 | 0.403 |
| Between 40 and 60 | 44 (25.4) | 33 | 11 | 75.0 | |
| ≥60 | 123 (71.1) | 103 | 20 | 83.7 | |
| Grading | |||||
| Grade 1 (Ki67 <2%) | 45 (26.0) | 39 | 6 | 86.6 | 0.022 |
| Grade 2 (Ki67 3%–20%) | 71 (41.0) | 59 | 12 | 83.1 | |
| Grade 3 (Ki67 >20%) | 11 (6.4) | 6 | 5 | 54.5 | |
| Unknown | 46 (26.6) | 36 | 10 | 78.3 | Not included |
| Primary tumor location | |||||
| Midgut or foregut | 81 (46.8) | 72 | 9 | 88.9 | 0.007 |
| Pancreatic | 40 (23.1) | 27 | 13 | 67.5 | |
| Bronchial | 12 (6.9) | 10 | 2 | 83.3 | |
| Chromaffin tissues | 5 (2.9) | 5 | 0 | 100 | |
| Head & neck | 2 (1.2) | 2 | 0 | 100 | |
| Spinal cord | 1 (0.6) | 0 | 1 | 0 | |
| Thymus | 1 (0.6) | 0 | 1 | 0 | |
| Unknown | 31 (17.9) | 25 | 6 | 80.6 | Not included |
| Neuroendocrine subtype | |||||
| Carcinoma | 158 (91.3) | 128 | 30 | 81.0 | 0.247 |
| Pheochromocytoma | 4 (2.3) | 4 | 0 | 100 | |
| Gastrinoma | 1 (0.6) | 0 | 1 | 0 | |
| Glucagonomas | 1 (0.6) | 1 | 0 | 100 | |
| Neuroblastoma | 1 (0.6) | 0 | 1 | 0 | |
| Paragangliomas | 1 (0.6) | 1 | 0 | 100 | |
| More than 1 subtype (MEN-1) | 3 (1.7) | 3 | 0 | 100 | |
| Not indicated in the medical chart | 4 (2.3) | 4 | 0 | 100 | Not included |
*
Univariate analysis was performed by the Fisher exact test with statistical significance set at P < 0.05. The univariate analysis was used to determine if there was a difference in therapy completion or discontinuation between the subgroups of sex, age, grading, primary tumor location, and neuroendocrine subtype.
Significant P<0.05 values are in bold
MEN-1 indicates multiple endocrine neoplasia type 1.